Microscopic Polyangiitis
📧 Sign up to get email alerts when something new happens for Microscopic Polyangiitis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-06-03FDA Approved: TAVNEOS — Supplemental Application (ChemoCentryx, Inc.)
The FDA approved a supplemental application for TAVNEOS (avacopan) submitted by ChemoCentryx, expanding its regulatory status for the treatm…
-
CLINICAL_TRIALS trial_result · 2022-09-27Clinical Trial Update: Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis [Phase 3]
A Phase 3 trial evaluating rituximab for good prognosis microscopic polyangiitis is reported with efficacy and safety data being collected, …
-
CLINICAL_TRIALS trial_result · 2022-09-09Clinical Trial Update: A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis [Phase 3]
Phase 3 trial of avacopan (CCX168) in ANCA-associated vasculitis has completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2022-08-25Clinical Trial Update: Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis. [Phase 2]
Phase 2 clinical trial updating the use of IFX-1 as an alternative to steroids in Granulomatosis with Polyangiitis and Microscopic Polyangii…
-
CLINICAL_TRIALS trial_result · 2022-07-06Clinical Trial Update: A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis [Phase 4]
Phase 4 trial evaluating safety and efficacy of rituximab combined with glucocorticoids in Wegener's Granulomatosis (granulomatosis with pol…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-06-03FDA Approved: RIABNI — Supplemental Application (Amgen, Inc)
FDA approved a supplemental application for RIABNI (rituximab-arrx) from Amgen. The action updates RIABNI’s labeling to reflect its approved…
-
CLINICAL_TRIALS trial_result · 2022-05-26Clinical Trial Update: Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA [Phase 2]
Phase 2 safety and efficacy study of IFX-1 add-on to standard of care in GPA and MPA was terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2022-03-18Clinical Trial Update: Rituximab Vasculitis Maintenance Study [Phase 3]
Phase 3 clinical trial update for rituximab maintenance in ANCA-associated vasculitis, including microscopic polyangiitis and Wegener granul…
-
FDA approval · 2021-10-07FDA Approved: TAVNEOS — Original Application (ChemoCentryx, Inc.)
FDA approved Tavneos (avacopan) from ChemoCentryx for adults with ANCA-associated vasculitis, in combination with standard therapy, includin…
-
EMA withdrawal · 2021-08-16EMA Withdrawn: Ritemvia (rituximab) — Celltrion Healthcare Hungary Kft.
EMA withdrawal of Ritemvia (rituximab) by Celltrion Healthcare Hungary Kft., affecting indications in lymphoma (non-Hodgkin) and vasculitic …
-
CLINICAL_TRIALS trial_result · 2021-01-27Clinical Trial Update: Low-dose Glucocorticoid Vasculitis Induction Study [Phase 4]
Phase 4 clinical trial update investigating low-dose glucocorticoids for induction in vasculitis conditions.
-
FDA approval · 2020-12-17FDA Approved: RIABNI — Original Application (Amgen, Inc)
FDA approved RIABNI (rituximab-arrx) from Amgen as a biosimilar to rituximab via Original Application.
-
EMA withdrawal · 2020-06-24EMA Application withdrawn: Rituximab Mabion (rituximab) — Mabion Spolka Akcyjna
The EMA application for Rituximab Mabion (rituximab) by Mabion Spolka Akcyjna has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2020-05-26Clinical Trial Update: Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis [Phase 3]
Phase 3 trial updating the use of plasma exchange and glucocorticoids for ANCA-associated vasculitis, with completion and results posted.
-
FDA approval · 2019-07-23FDA Approved: RUXIENCE — Original Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved Ruxience (rituximab-pvvr) from Pfizer as a biosimilar to rituximab, under an original application; the approval covers multiple…
-
EMA withdrawal · 2019-07-08EMA Withdrawn: Rituzena (previously Tuxella) (rituximab) — Celltrion Healthcare Hungary Kft.
EMA withdrew Rituzena (rituximab) from the market (formerly Tuxella), with the decision dated 28 January 2019.
-
CLINICAL_TRIALS trial_result · 2019-06-26Clinical Trial Update: A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis [Phase 2]
Phase IIa study evaluating intravenous rituximab in pediatric participants with granulomatosis with polyangiitis or microscopic polyangiitis…
-
FDA approval · 2019-05-23FDA Approved: TRUXIMA — Supplemental Application (Cephalon, Inc.)
FDA approved a supplemental application for TRUXIMA (rituximab-ABBS) submitted by Cephalon, Inc.
-
CLINICAL_TRIALS trial_result · 2018-08-17Clinical Trial Update: Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis [Phase 4]
A Phase 4 pilot study evaluating short-course glucocorticoids plus rituximab for ANCA-associated vasculitis has completed with posted result…
-
CLINICAL_TRIALS research · 2018-06-06Clinical Trial Update: Journey of Patients With Vasculitis From First Symptom to Diagnosis
A completed University of Pennsylvania clinical study tracks vasculitis patients from first symptoms through diagnosis, describing the diagn…
-
CLINICAL_TRIALS trial_result · 2017-10-27Clinical Trial Update: Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study
This clinical trial update reports long-term follow-up results from the RAVE study evaluating rituximab for ANCA-associated vasculitis, incl…
-
FDA approval · 2017-06-22FDA Approved: RITUXAN HYCELA — Original Application (Genentech, Inc.)
FDA approved RITUXAN HYCELA (rituximab and hyaluronidase) under an Original Application by Genentech. The subcutaneous formulation provides …
-
FDA label_change · 2017-06-22FDA Approved: RITUXAN HYCELA — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Rituxan Hycela (rituximab and hyaluronidase) by Genentech, updating the labeling for this subcut…
-
CLINICAL_TRIALS trial_result · 2017-05-04Clinical Trial Update: The ANCA Vasculitis Questionnaire (AAV-PRO©)
The ANCA Vasculitis Questionnaire (AAV-PRO©) trial update notes that the study evaluating a patient-reported outcome instrument for ANCA-ass…
-
CLINICAL_TRIALS research · 2016-08-19Clinical Trial Update: American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis
This clinical trial update describes progress on the ACR/EULAR diagnostic and classification criteria for primary systemic vasculitis, spons…